J B Chemicals & Pharmaceuticals Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 49.9. ROE: 18.9%. This stock is not currently in the Nifty 500 momentum outperformers list.
Earnings deceleration risks from management commentary
Trigger: Post-merger, JB Pharma ceases to exist as a listed entity; shareholders receive 51 Torrent shares per 100 JB Pharma shares — the risk is the merger consideration undervaluing JB's intrinsic trajectory, and the strategic restructuring of zero-margin trade generics post-Torrent control
Monitor: regulatory
Trigger: One-time charges will suppress reported PAT and EPS in the quarter they are recognized; however, these are known, quantified, and already flagged to the market — no surprise risk
Monitor: regulatory
Trigger: Commodity risk is structurally low for a branded pharma formulator — pricing power in domestic chronic segment and long-term CDMO contracts provide adequate buffer
Monitor: commodity
Trigger: Sustained Russia exposure post-Ukraine conflict creates long-term collectability and currency risk — manageable at current scale but worth monitoring as international business grows
Monitor: geopolitical
Key quotes from recent conference calls
“The acquisition of a controlling stake in JB Pharma is expected to bring significant cost synergies, estimated at INR 400-450 crore over the next two to three years. The trade generics business of JB Pharma is running at zero margin and may require restructuring or discontinuation (per Torrent's Q3 FY26 commentary) [Risk (regulatory): HIGH]”
“A key upcoming event is the closure of the Torrent merger in Q4 FY26, which may trigger a one-time ESOP charge of approximately INR 40 crore. The company continues to monitor regulatory changes, including new Labour Codes, and will adjust financial reporting as needed [Risk (regulatory): MEDIUM]”
“Gross margins improved due to better product mix, stable RM prices and positive price growth [Risk (commodity): LOW]”
“All the exports businesses viz. South Africa, Russia, USA and branded exports markets performed well for the quarter [Risk (geopolitical): LOW]”
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 30, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
J B Chemicals & Pharmaceuticals Ltd's latest quarterly results (Mar 2026) show
J B Chemicals & Pharmaceuticals Ltd's current PE ratio is 49.9x.
J B Chemicals & Pharmaceuticals Ltd's price-to-book ratio is 8.6x.
J B Chemicals & Pharmaceuticals Ltd's fundamental strength based on key financial ratios
J B Chemicals & Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
J B Chemicals & Pharmaceuticals Ltd's return ratios over recent years
J B Chemicals & Pharmaceuticals Ltd's operating cash flow is positive (FY2026).
J B Chemicals & Pharmaceuticals Ltd's current dividend yield is 0.99%.
J B Chemicals & Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
J B Chemicals & Pharmaceuticals Ltd's promoter holding has increased recently.
J B Chemicals & Pharmaceuticals Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
J B Chemicals & Pharmaceuticals Ltd has 4 key risks worth monitoring
In Q3 FY26, J B Chemicals & Pharmaceuticals Ltd's management highlighted
Based on quantitative research signals, here is why J B Chemicals & Pharmaceuticals Ltd may be worth studying
J B Chemicals & Pharmaceuticals Ltd investment thesis summary:
J B Chemicals & Pharmaceuticals Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
